secwatch.observer — SEC 8-K summary
======================================

Issuer:     INVO Fertility, Inc. (IVF)
CIK:        0001417926
Form:       8-K
Filed at:   2023-04-17T23:59:59+00:00
Accession:  0001493152-23-012538
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INVO Bioscience reports 2022 revenue $0.8M, cash $0.1M; EBITDA loss widens to $(8.4)M
--------------------------------------------------------------------------------

- FY 2022 revenue $822K (up 40% excl. Ferring license); Q4 revenue $278K, up 18% sequentially.
- Adjusted EBITDA loss of $(8.4)M vs $(2.8)M in 2021; includes $0.3M acquisition costs and IP write-down.
- Cash $0.1M at Dec 31, 2022; $3.0M gross raised in March 2023 registered direct offering.
- Signed binding agreement to acquire Wisconsin Fertility Institute for $10M payable over 3 years; expected close Q2 2023.
- Clinic revenue from all centers up 726% to $1.6M; Atlanta center contributed $614K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1417926/000149315223012538/0001493152-23-012538-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1417926/000149315223012538/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-012538

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer